Repositioning Candidate Details
| Candidate ID: | R1314 |
| Source ID: | DB09496 |
| Source Type: | approved; investigational |
| Compound Type: | small molecule |
| Compound Name: | Octinoxate |
| Synonyms: | ethylhexyl methoxycinnamate; ethylhexyl p-methoxycinnamate; Octinoxate; octyl methoxycinnamate; parsol |
| Molecular Formula: | C18H26O3 |
| SMILES: | [H]\C(=C(\[H])C1=CC=C(OC)C=C1)C(=O)OCC(CC)CCCC |
| Structure: |
|
| DrugBank Description: | Octinoxate is a cinnamate ester and common ingredient in sunscreen and other skin care products to minimize DNA photodamage. It was originally developed in 1950's as an organic UV-B filter that absorbs UV-B rays from sun. It is often combined with nanoparticles or other water-resistant liposomes in formulations to increase the localization at the epidermis and decrease the risk of percutaneous absorption. Its use in pharmaceutical and cosmetic formulations is approved by FDA. |
| CAS Number: | 5466-77-3 |
| Molecular Weight: | 290.3972 |
| DrugBank Indication: | As an active ingredient in sunscreens and lip balms. Used for protection against damaging effects of sun rays. |
| DrugBank Pharmacology: | Acts as a photoprotective agent that protects the skin by preventing and minimizing the damaging effects of ultraviolet (UV) rays of natural light. The cellular effects of UV irradiation include DNA damage, cell cycle arrest, immunological depression, apoptosis, and transcriptional changes . |
| DrugBank MoA: | Absorbs UV-B (predominantly) and UV-A rays while accumulating in the outermost layer of the epidermis. Like any other photoprotective agents, octinoxate prevents the damage to cells and deoxyribonucleic acid (DNA) by reducing the p53 protein expression following UV exposure and also increases the skin's tolerability to UV rays . |
| Targets: | -- |
| Inclusion Criteria: | Therapeutic strategy associated |
